论文部分内容阅读
用卡铂建立的猴骨髓抑制模型观察国产重组人白细胞介素 11(rhIL 11)对血小板减少症的治疗作用。给予模型动物rhIL 115 0或 10 0 μg/kg皮下注射 ,连续 19天。给rhIL 11治疗的猴血小板计数从第 8天开始下降 ,在第 12 - 14天达最低点 ,其下降程度远低于模型动物。rhIL 11治疗后 11- 13天血小板计数开始回升 ,13- 15天达到或超过建立模型前水平 ,停药后血小板数继续升高 ,并维持在高水平。停药 4天后血小板计数开始回落。实验结果证实rhIL 11具有显著的促血小板生成的作用 ,不仅可以缩短卡铂引起的血小板减少症的持续时间 ,而且可以减轻血小板减少症的严重程度。结论提示rhIL 11可作为治疗化疗引起的血小板减少症的有效药物。
The use of carboplatin monkey bone marrow suppression model observed domestic recombinant human interleukin 11 (rhIL 11) on the treatment of thrombocytopenia. Model animals were given subcutaneous injections of rhIL 115 or 10 0 μg / kg for 19 consecutive days. Monkey platelet counts for rhIL-11 treatment decreased from day 8 and reached the lowest point on days 12 to 14, much less than in model animals. Platelet counts began to rise 11 to 13 days after rhIL 11 treatment and reached or exceeded pre-model levels on days 13-15. The number of platelets continued to increase after treatment and remained high. After 4 days withdrawal platelet count began to fall. Experimental results confirmed that rhIL 11 has a significant role in promoting platelet production, not only can shorten the duration of carboplatin-induced thrombocytopenia, and can reduce the severity of thrombocytopenia. Conclusions suggest that rhIL 11 can be used as an effective drug in the treatment of chemotherapy-induced thrombocytopenia.